Since their introduction 20 years ago, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionised the treatment of diabetes and obesity. Known for their immunomodulatory and ...
The landscape of weight management has evolved dramatically in recent years, with GLP-1 receptor agonists like Semaglutide leading the way in treating obesity. However, a new contender has emerged: ...
MEDVi, a telehealth platform serving more than 100,000 patients, today announced an expanded physician-led program ...
The phase 2 trial of CT-388, a once-weekly subcutaneous injection acquired as part of its $2.7 billion takeover of Carmot ...
Share on Pinterest The WHO recommended GLP-1s as a treatment for obesity alongside a healthy diet and regular exercise. Milles Team/Stocksy New guidelines from the World Health Organization (WHO) ...
While they slash appetite, they do not reduce the body’s need for essential nutrients ...
Everyday Health on MSN
How to avoid GLP-1 side effects if you have type 2 diabetes
GLP-1 agonists and dual agonists can cause hypoglycemia, nausea, and more. Here's how to lessen the side effects.
Friendly” labels on the packaging are becoming more common in U.S. supermarkets as a growing number of Americans ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results